Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms ASPIRE-HIGHER; ATMOSPHERE
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Dec 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
- 28 Aug 2023 Results presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 29 Aug 2022 Results of pooled analysis assessing aimed to evaluate the current incidence of stroke in patients with HFrEF not in AF receiving modern pharmacological therapy and to validate our stroke prediction model presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology